APRESOLINE

This brand name is authorized in Canada, Ireland, Japan, New Zealand, Singapore, United Kingdom, South Africa

Active ingredients

The drug APRESOLINE contains one active pharmaceutical ingredient (API):

1 Hydralazine UNII FD171B778Y - HYDRALAZINE HYDROCHLORIDE

Hydralazine is a direct acting vasodilator which exerts its effects principally on the arterioles. Its precise mode of action is not known. Read about Hydralazine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
APRESOLINE Solution for injection	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C02DB02	Hydralazine	C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DB Hydrazinophthalazine derivatives
Discover more medicines within C02DB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 00723754
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 13912
Country: IE	Health Products Regulatory Authority	Identifier(s): 12831
Country: JP	医薬品医療機器総合機構	Identifier(s): 2142004B2163, 2142004F1053, 2142004F2025, 2142004F3056
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 2357
Country: SG	Health Sciences Authority	Identifier(s): 00509P
Country: ZA	Health Products Regulatory Authority	Identifier(s): H/7.1.3/525, Q/7.1.3/180